Promising colorectal cancer combo trial halted early
NCT ID NCT03426371
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tested whether adding the experimental drug A140 to standard chemotherapy (mFOLFOX6) could help people with a specific type of advanced colorectal cancer (RAS wild-type) live longer without their cancer growing. The trial planned to enroll 570 people in China but was stopped early after only 52 participants. The goal was to see if the combination improved progression-free survival compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
307 Hospital of PLA
Beijing, Beijing Municipality, 100071, China
Conditions
Explore the condition pages connected to this study.